Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center.

Breast disease Pub Date : 2024-01-01 DOI:10.3233/BD-230044

Sabas Carlos Vieira, Cristiane Amaral Dos Reis, Mariana Elvas Feitosa Holanda, Danilo Rafael da Silva Fontinele, Alessandro Igor Cavalcanti Leal, Fernanda Teresa de Lima

{"title":"Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center.","authors":"Sabas Carlos Vieira, Cristiane Amaral Dos Reis, Mariana Elvas Feitosa Holanda, Danilo Rafael da Silva Fontinele, Alessandro Igor Cavalcanti Leal, Fernanda Teresa de Lima","doi":"10.3233/BD-230044","DOIUrl":null,"url":null,"abstract":"Objective: We aim to evaluate the indication and use of genomic signatures in breast cancer patients and outcomes who in patients undergoing adjuvant chemotherapy or not.Methods: This is a retrospective study of breast cancer patients managed in a private oncology clinic in Teresina, from November 2014 to February 2021. All patients with an indication of genomic signature were included. Clinical and pathological variables, use of genomic signatures, treatment and follow-up were obtained. The nomogram to predict Oncotype DX results (University of Tennessee Medical Center) was also calculated. Clinical risk calculation was based on MINDACT, using the modified version of Adjuvant Online. The genetic signatures performed were: the Oncotype, MammaPrint and EndoPredict.Results: Fifty (50) female patients were included in the study. The mean age of the participants was 57.1 years. Among the patients receiving a genomic signature (26-52.0%), there was a change in treatment in 8 (30.7%) cases. Chemotherapy was indicated in four patients, It was contraindicated in another four patients. Treatment changed in 30.7% of the tested patients. Chemotherapy was indicated for those who would not receive it before. It was contraindicated in patients who would previously undergo chemotherapy.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"237-242"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307088/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-230044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We aim to evaluate the indication and use of genomic signatures in breast cancer patients and outcomes who in patients undergoing adjuvant chemotherapy or not.

Methods: This is a retrospective study of breast cancer patients managed in a private oncology clinic in Teresina, from November 2014 to February 2021. All patients with an indication of genomic signature were included. Clinical and pathological variables, use of genomic signatures, treatment and follow-up were obtained. The nomogram to predict Oncotype DX results (University of Tennessee Medical Center) was also calculated. Clinical risk calculation was based on MINDACT, using the modified version of Adjuvant Online. The genetic signatures performed were: the Oncotype, MammaPrint and EndoPredict.

Results: Fifty (50) female patients were included in the study. The mean age of the participants was 57.1 years. Among the patients receiving a genomic signature (26-52.0%), there was a change in treatment in 8 (30.7%) cases. Chemotherapy was indicated in four patients, It was contraindicated in another four patients. Treatment changed in 30.7% of the tested patients. Chemotherapy was indicated for those who would not receive it before. It was contraindicated in patients who would previously undergo chemotherapy.

查看原文本刊更多论文

现实世界中乳腺癌的基因组特征：巴西东北部中心的经验。

目的我们旨在评估基因组特征在乳腺癌患者中的适应症和使用情况，以及患者是否接受辅助化疗的结果：这是一项回顾性研究，研究对象是 2014 年 11 月至 2021 年 2 月期间在特雷西纳一家私人肿瘤诊所接受治疗的乳腺癌患者。所有有基因组特征指征的患者均被纳入研究范围。研究人员了解了临床和病理变量、基因组特征的使用、治疗和随访情况。还计算了预测 Oncotype DX 结果的提名图（田纳西大学医学中心）。临床风险计算以 MINDACT 为基础，使用改良版的 Adjuvant Online。进行的基因特征描述包括：Oncotype、MammaPrint 和 EndoPredict：研究共纳入了 50 名女性患者。参与者的平均年龄为 57.1 岁。在接受基因组特征分析的患者中（26-52.0%），有 8 例（30.7%）改变了治疗方案。4名患者接受了化疗，另有4名患者禁用化疗。30.7%的受检患者改变了治疗方法。化疗适用于以前不接受化疗的患者。之前接受过化疗的患者禁忌化疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.